TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
EyePoint Pharmaceuticals ( (EYPT) ) has provided an announcement.
On November 19, 2025, EyePoint Pharmaceuticals announced a positive recommendation from the independent Data Safety Monitoring Committee for its ongoing pivotal Phase 3 trials of DURAVYU for treating wet age-related macular degeneration (wet AMD). The trials, named LUGANO and LUCIA, have shown no safety signals, and the DSMC recommended continuing without protocol changes. This strengthens confidence in DURAVYU’s safety profile, with topline data expected in mid-2026. The trials are significant as they evaluate a sustained release treatment potentially reducing the treatment burden for wet AMD, a condition requiring frequent interventions.
The most recent analyst rating on (EYPT) stock is a Hold with a $13.50 price target. To see the full list of analyst forecasts on EyePoint Pharmaceuticals stock, see the EYPT Stock Forecast page.
Spark’s Take on EYPT Stock
According to Spark, TipRanks’ AI Analyst, EYPT is a Neutral.
EyePoint Pharmaceuticals’ overall stock score reflects its significant financial challenges and unprofitability, offset by strong clinical progress and a solid cash position. The company’s strategic focus on innovative treatments and potential market leadership in the biotechnology sector are positive indicators, but financial improvements are crucial for long-term success.
To see Spark’s full report on EYPT stock, click here.
More about EyePoint Pharmaceuticals
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for serious retinal diseases. The company’s lead product candidate, DURAVYU, is an investigational sustained delivery treatment combining vorolanib, a selective tyrosine kinase inhibitor, with next-generation bioerodible Durasert E technology. EyePoint is headquartered in Watertown, Massachusetts, and has a commercial manufacturing facility in Northbridge, Massachusetts.
Average Trading Volume: 1,215,762
Technical Sentiment Signal: Buy
Current Market Cap: $1.09B
For detailed information about EYPT stock, go to TipRanks’ Stock Analysis page.